HEALTH

Zewa establishes personal health data depot for consumers with suite of products

BY Michael Johnsen

FORT MYERS, Fla. — Zewa recently launched its first Bluetooth 4.0 enabled monitoring devices which include a Blood Pressure Monitor, Scale with Body Fat function and an Activity Tracker. All three devices connect to Zewa’s MyHealthConnected App and online health tracking platform. 
 
The MyHealthConnected app enables patients to share their vital signs by automatically collecting information from Zewa Bluetooth devices and sharing the information with healthcare providers, hospitals, pharmacists and family. 
 
Zewa’s Bluetooth Blood Pressure Monitor features a 180 reading memory, date and time along with a large backlit display. It automatically transfers measurements to Zewa’s app or saves it in its internal memory until a smart device is in range. The Bluetooth Scale features a “step on” function and measures weight, Body Fat % and BMI (BMI is calculated in the App). 
 
The third device is a Bluetooth enabled Activity Tracker. It is worn like a watch and features a LED display which displays time, steps, distance and calories. The App will also track sleep and allows the user to set an alarm.
 
Zewa’s MyHealthConnected App connects to all three devices making it easy to track health. Information is saved
over time giving a user complete control of tracking their own health.
 
Zewa also launched an online health tracking platform, called MyHealthConnected. Once data is collected by the app, the information can be linked to an online cloud account. A patient can access their own information or have it linked to a healthcare provider or pharmacy. 
 
MyHealthConnected is a HIPAA compliant and FDA approved class 1 medical device platform, the company stated. 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
HEALTH

Target’s Made to Matter program to feature Zarbee’s Naturals new baby supplement line

BY Michael Johnsen

 

 
 
SALT LAKE CITY — Zarbee's Naturals on Tuesday introduced a Target-exclusive line of natural baby vitamins and supplements for infants and toddlers. 
 
"We're proud to introduce a new line of vitamins and supplements that provide a full range of wellness solutions for moms with infants and toddlers," said Bret Furio, CEO Zarbee's Naturals. "We're also pleased to share that this new line has been selected by Target to be a part of their 2015 Made to Matter collection of leading natural, organic and sustainable brands."
 
Zarbee's line of new baby vitamins and supplements are pediatrician recommended and contain natural ingredients such as agave and coconut oil to provide safe and effective solutions for growing babies. The line features probiotic Lcr35, which helps restore and maintain balance in your baby's digestive system. The products are gluten-free, dye­free and contain no drugs or alcohol.
 
The new line includes:
 
  • Baby Probiotic Supplement: Zarbee's Baby Probiotic supplement promotes and maintains intestinal health by restoring the natural balance in the baby's digestive tract. The proprietary 3Biotic formula contains a prebiotic, probiotic and natural postbiotic to increase delivery of this beneficial bacteria to the child's digestive system;
  • Baby Vitamin D Supplement: This supplement delivers vitamin D in a natural coconut oil to help absorb calcium for strong bones and teeth. The American Academy of Pediatrics recommends supplementing a breastfed infant with 400 IUs of vitamin D daily since an adequate amount of vitamin D is not transferred through breast milk;
  • Baby Omega-3: Zarbee's Omega-3 DHA supplement is formulated with plant-based DHA and natural coconut oil. Adequate intake of DHA has been shown to support brain, eye and nervous system development during all stages of life; and
  • Baby Multi Vitamin with Iron Supplement: This multivitamin is specially designed to meet the needs of a growing infant and toddler. It delivers 100% of the daily recommended value for infants of nine essential vitamins including vitamins A, C and D as well as iron.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
HEALTH

Nutramax to form expert panel to improve G/C guidelines

BY Michael Johnsen

EDGEWOOD, Md. — Nutramax Laboratories Consumer Care on Tuesday announced plans to assemble a panel of joint health experts to review current American Academy of Orthopaedic Surgeons guidance on the use of glucosamine/chondroitin sulfate supplements for joint health. The panel will focus specifically on the most recent AAOS Evidence-based Guideline for using joint health supplements and provide its recommendation based on a growing body of clinical evidence. 
 
"The very positive results from recent trials of glucosamine and chondroitin sulfate support our published research from 1999 and 2000," stated Robert Henderson, chairman Nutramax Laboratories. "In light of those results, it is time to start a dialog with the AAOS to review the accumulated clinical evidence regarding the combined use of glucosamine and chondroitin sulfate for joint health."  
 
Recently published randomized, controlled trials using high-quality, pharmaceutical-grade glucosamine and chondroitin sulfate, at a daily dose of 1,500 and 1,200 milligrams, respectively, have produced very positive outcomes for patient populations in the studies.
 
Under the guidance of Brian Cornblatt, medical director of Nutramax Laboratories, the panel of experts will review the available clinical evidence supporting the use of glucosamine/chondroitin sulfate supplementation in promoting joint health, and work with the AAOS guideline committee to explore consideration of this evidence in the third edition of the Evidence-based Guideline. The members of the task force will focus special attention on the following recent publications:
 
  • MOVES (Multicentre Osteoarthritis InterVEntion trial with Sysadoa): This study provides the most recent evidence to support the use of glucosamine hydrochloride and chondroitin sulfate, at a daily dose of 1,500 and 1,200 milligrams, respectively, in managing joint health in a wide variety of patient populations. The results were published in January 2015 in the online edition of Annals of the Rheumatic Diseases;
  • GAIT (Glucosamine/Chondroitin Arthritis Intervention Trial): Published in The New England Journal of Medicine in 2006, the GAIT study showed that glucosamine hydrochloride and chondroitin sulfate, at the same daily dose as used in the MOVES trial, may be a viable option in a subgroup of patients with moderate to severe joint discomfort. The MOVES study was developed as an extension of the GAIT study;
  • Brazilian Trial (Prospective, Multi-Center, Randomized Controlled Trial): In an international, head-to-head study involving more than 900 participants, a team of Brazilian researchers found that Nutramax Laboratories' CosaminDS, which contains 1,500 mg of glucosamine hydrochloride and 1,200 mg of chondroitin sulfate in capsule form, and a Brazilian prescription brand containing the same doses of these ingredients either as a sachet or a capsule formulation, were equally effective. The researchers, who published their results in Clinical Rheumatology in August 2014, reported statistically significant improvements in joint comfort and physical function as measured by change from baseline using a visual analog scale and the Lequesne Index, a measure of osteoarthritis severity. They also observed no significant alterations in laboratory values assessing safety, including fasting glycemia; and
  • Cochrane Review: In a review published in January 2015, the Cochrane Collaborative characterized chondroitin sulfate as more effective than placebo in improving pain and physical function in patients with osteoarthritis, with a lower risk of adverse events. The Cochrane review – the most comprehensive review of chondroitin sulfate published to date – examined data from 43 randomized, controlled, short-term trials involving 4,962 participants treated with chondroitin sulfate and 4,148 participants who were given a placebo or another control, and concluded that the benefit of chondroitin sulfate in these studies was clinically meaningful.
 
"Our aim is to explore whether current guidelines accurately reflect real-world experience and recent clinical evidence supporting the use of high-quality glucosamine and chondroitin to support joint health," said Nicholas DiNubile, an orthopedic surgeon. "It is important that we open discussions with our colleagues about the role of supplements and to achieve a better understanding of when and where high-quality supplements fit into the overall joint health management paradigm."
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?